Literature DB >> 18922635

Immunological characteristics of experimental murine infection with Leishmania (Leishmania) amazonensis.

Bernardo Acácio Santini Pereira1, Carlos Roberto Alves.   

Abstract

The murine models of Leishmania infection are well-studied and suitable models for studying this disease, which, despite its incidence of nearly 2 million new cases worldwide per year and its prevalence of 12 million cases, has been a somewhat neglected disease. Data obtained using such models are important for a better understanding of the disease in humans due to similarities in physiology and the advantage provided by the uniform infection profile within each mouse strain. In this review, we focus on studies of experimental murine infection with Leishmania (Leishmania) amazonensis, a species that has been associated with infections exhibiting various clinical features in humans. Mainly, we point out and discuss reports on: the effects of variations of the inoculum (such as strain, site, and size) in the establishment and development of the infection; characteristics of the infection in distinct mouse strains; and, the effects and subversions of the infection on components of the host innate and adaptive immune responses. The results obtained in these studies show that L. (L.) amazonensis infection in mice presents some unique features and immunoregulatory mechanisms, making it an interesting model for obtaining further knowledge of potential drugs targets and immunotherapy in Leishmania infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18922635     DOI: 10.1016/j.vetpar.2008.09.015

Source DB:  PubMed          Journal:  Vet Parasitol        ISSN: 0304-4017            Impact factor:   2.738


  29 in total

Review 1.  Immunopathogenesis of non-healing American cutaneous leishmaniasis and progressive visceral leishmaniasis.

Authors:  Lynn Soong; Calvin A Henard; Peter C Melby
Journal:  Semin Immunopathol       Date:  2012-10-11       Impact factor: 9.623

2.  A Leishmania-specific hypothetical protein expressed in both promastigote and amastigote stages of Leishmania infantum employed for the serodiagnosis of, and as a vaccine candidate against, visceral leishmaniasis.

Authors:  Vivian T Martins; Mariana C Duarte; Miguel A Chávez-Fumagalli; Daniel Menezes-Souza; Cecília S P Coelho; Danielle F de Magalhães-Soares; Ana Paula Fernandes; Manuel Soto; Carlos A P Tavares; Eduardo A F Coelho
Journal:  Parasit Vectors       Date:  2015-07-11       Impact factor: 3.876

3.  CXCL10 production by human monocytes in response to Leishmania braziliensis infection.

Authors:  Diego A Vargas-Inchaustegui; Alison E Hogg; Gianfranco Tulliano; Alejandro Llanos-Cuentas; Jorge Arevalo; Janice J Endsley; Lynn Soong
Journal:  Infect Immun       Date:  2009-11-09       Impact factor: 3.441

4.  An antigenic domain of the Leishmania amazonensis nucleoside triphosphate diphosphohydrolase (NTPDase 1) is associated with disease progression in susceptible infected mice.

Authors:  M L Detoni; M R Fessel; A C R G Maia; G N Porcino; L R Quellis; P Faria-Pinto; M J Marques; M A Juliano; L Juliano; V A Diniz; S Côrte-Real; S C Gonçalves-da-Costa; C S F Souza; E G Vasconcelos
Journal:  Parasitol Res       Date:  2013-05-17       Impact factor: 2.289

5.  Dual Host-Intracellular Parasite Transcriptome of Enucleated Cells Hosting Leishmania amazonensis: Control of Half-Life of Host Cell Transcripts by the Parasite.

Authors:  Cristina M Orikaza; Carina C Pessoa; Fernanda V Paladino; Pilar T V Florentino; Clara L Barbiéri; Hiro Goto; Eduardo Milton Ramos-Sanchez; José Franco da Silveira; Michel Rabinovitch; Renato A Mortara; Fernando Real
Journal:  Infect Immun       Date:  2020-10-19       Impact factor: 3.441

6.  In silico predicted epitopes from the COOH-terminal extension of cysteine proteinase B inducing distinct immune responses during Leishmania (Leishmania) amazonensis experimental murine infection.

Authors:  Bernardo A S Pereira; Franklin S Silva; Karina M Rebello; Marcel Marín-Villa; Yara M Traub-Cseko; Thereza C B Andrade; Álvaro L Bertho; Ernesto R Caffarena; Carlos R Alves
Journal:  BMC Immunol       Date:  2011-08-08       Impact factor: 3.615

Review 7.  Quantity and Quality of Inhaled Dose Predicts Immunopathology in Tuberculosis.

Authors:  Kevin P Fennelly; Edward C Jones-López
Journal:  Front Immunol       Date:  2015-06-29       Impact factor: 7.561

8.  AgNP-PVP-meglumine antimoniate nanocomposite reduces Leishmania amazonensis infection in macrophages.

Authors:  Ana Patricia Cacua Gélvez; José Antonio Picanço Diniz Junior; Rebecca Thereza Silva Santa Brígida; Ana Paula Drummond Rodrigues
Journal:  BMC Microbiol       Date:  2021-07-12       Impact factor: 3.605

9.  Antigenicity and protective efficacy of a Leishmania amastigote-specific protein, member of the super-oxygenase family, against visceral leishmaniasis.

Authors:  Vivian T Martins; Miguel A Chávez-Fumagalli; Lourena E Costa; Adriana M C Canavaci; Adriana M C C Martins; Paula S Lage; Daniela P Lage; Mariana C Duarte; Diogo G Valadares; Rubens D M Magalhães; Tatiana G Ribeiro; Ronaldo A P Nagem; Wanderson D Darocha; Wiliam C B Régis; Manuel Soto; Eduardo A F Coelho; Ana Paula Fernandes; Carlos A P Tavares
Journal:  PLoS Negl Trop Dis       Date:  2013-03-28

10.  HIV aspartyl peptidase inhibitors interfere with cellular proliferation, ultrastructure and macrophage infection of Leishmania amazonensis.

Authors:  Lívia O Santos; Fernanda A Marinho; Ellen F Altoé; Bianca S Vitório; Carlos R Alves; Constança Britto; Maria Cristina M Motta; Marta H Branquinha; André L S Santos; Claudia M d'Avila-Levy
Journal:  PLoS One       Date:  2009-03-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.